Independent academic projectNot an official Nemaura Medical website

About Us · Company background

A small medtech company with a needle-free ambition.

Nemaura Medical has focused on making glucose trends easier to observe through wearable sensors and digital health programs.

Founded2013
Operating baseLoughborough, UK
Market symbolNMRD · OTC

OUR STORY

Built around the skin as a diagnostic interface.

Nemaura Medical Inc. was incorporated in Nevada in 2013, although some secondary profiles cite 2011 as its founding year. Its operating history also follows earlier work within related companies focused on transdermal delivery and diagnostic technologies.

Its flagship concept, sugarBEAT®, uses a flexible skin patch and a reusable transmitter to obtain and communicate glucose trend information without an inserted sensor filament. The company later extended this device idea into digital coaching programs such as proBEAT™ and BEAT® diabetes.

The business has remained small and development-led. Its commercial strategy has emphasized regulatory approvals, licensing arrangements, pilot programs, strategic partners, contract manufacturing and market-by-market scale-up.

Historically based at Loughborough Science Park in the United Kingdom, the organization is best understood as a development-to-commercialization medtech company rather than a mature, broadly scaled device manufacturer.

PURPOSE & APPROACH

Four ideas behind the company proposition.

01

Less invasive

Explore glucose monitoring without the inserted filament used by conventional CGMs.

02

Wear it your way

Position daily, intermittent wear as an alternative to continuous multi-day use.

03

See patterns

Turn frequent readings into trend information that can support informed decisions.

04

Connect care

Combine sensor information with coaching, digital programs and clinical partnerships.

COMPANY MILESTONES

From related pharma roots to wearable diagnostics.

2005Related roots

Nemaura Pharma Limited formed around skin drug-delivery systems.

2013Incorporated

Nemaura Medical Inc. was organized as a Nevada corporation; some secondary profiles cite 2011.

2018Public market

NMRD moved to the Nasdaq Capital Market.

2019CE Mark

sugarBEAT reached a major European regulatory milestone.

2023Saudi approval

SFDA approval was reported for sugarBEAT.

2024OTC transition

The company accepted Nasdaq delisting and moved to OTC markets.

Independent educational project

This website is not affiliated with Nemaura Medical Inc. and does not provide medical or investment advice.